Page last updated: 2024-11-10

retinol palmitate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

retinol palmitate: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

retinyl palmitate : A palmitate ester of retinol with undefined geometry about the C=C bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

all-trans-retinyl palmitate : An all-trans-retinyl ester obtained by formal condensation of the carboxy group of palmitic (hexadecanoic acid) with the hydroxy group of all-trans-retinol. It is used in cosmetic products to treat various skin disorders such as acne, skin aging, wrinkles, dark spots, and also protect against psoriasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280531
CHEMBL ID1675
CHEBI ID17616
CHEBI ID15040
SCHEMBL ID41649
MeSH IDM0063601

Synonyms (133)

Synonym
AC-20001
110067-62-4
CHEBI:17616 ,
all-trans-retinyl hexadecanoate
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl hexadecanoate
retinol, hexadecanoate
[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] hexadecanoate
D00164
aquasol a (tn)
retinol palmitate (jp17)
ccris 3280
optovit-a
retinol, palmitate, all-trans-
o~15~-hexadecanoylretinol
brn 1917366
vitamin a solubilized
einecs 201-228-5
retinol, all-trans-, palmitate
retinyl hexadecanoate
(2e,4e,6e,8e)-hexadecanoic acid 3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2, 4,6,8,tetraenyl ester
LMPR01090013
IDI1_000249
SPECTRUM5_001201
retinol palmitate (6ci,7ci)
trans-retinol palmitate
retinol, o~15~-(1-oxohexadecyl)-
lutavit a 500 plus
arovit
arovit (roche)
vitazyme a
dispatabs tabs
aquapalm
palmitic acid, ester with retinol
optovit a
trans-retinyl palmitate
all-trans-retinol palmitate
all-trans-vitamin a palmitate
retinol, palmitate, all-trans- (8ci)
axerophthol palmitate
C02588
all-trans-retinyl palmitate
retinyl palmitate
retinol palmitate
vitamin a palmitate
79-81-2
retinyl palmitate, potency: >=1,700,000 usp units per g
NCGC00095056-02
NCGC00095056-01
SPECTRUM1503604
MLS001332438
smr000112463
MLS001332437
retinol-palmitate
HMS2093G13
vitamin- a palmitate
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-en-1-yl)-2,4,6,8-nonateetraen-1-yl-palmitate
BMSE000501
HMS500M11
HMS1922E10
vitamin a palmitate (solubilized)
retinol, palmitate, all-trans
CHEMBL1675
all-(e)-retinol palmitate
nsc-758478
[3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] hexadecanoate
A839762
hexadecanoic acid [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenyl] ester
NCGC00095056-03
tox21_303008
dtxsid1021241 ,
NCGC00256427-01
cas-79-81-2
dtxcid101241
tox21_113452
nsc758478
pharmakon1600-01503604
AKOS015918435
HMS2268C06
S4126
CCG-39342
1d1k0n0vvc ,
ec 201-228-5
unii-1d1k0n0vvc
retinol palmitate [jan]
nsc 758478
retinyl palmitate [inci]
vitamin a palmitate (solubilized) [vandf]
vitamin a palmitate [mi]
retinol palmitate [who-dd]
vitamin a palmitate [orange book]
vitamin a (as palmitate & beta carotene) [vandf]
retinyl palmitate [vandf]
vitamin a palmitate [vandf]
all-(e)-retinol palmitate [who-ip]
retinyl palmitate [usp-rs]
3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl hexadecanoate
SCHEMBL41649
3,7-dimethyl-9-(2,6,6,-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol palmitate
AB00052360_04
vitamin a palmitate, 1.7 m.i.u./g
mfcd00019414
retinyl (vitamin a) palmitate
sr-05000001910
SR-05000001910-1
retinyl palmitate, united states pharmacopeia (usp) reference standard
retinyl hexadecanoic acid
retinyl palmitic acid
retinyl palmitate (vitamin a palmitate), pharmaceutical secondary standard; certified reference material
SBI-0051830.P002
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl palmitate
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl palmitate
Q7316807
vitamin a palmitate;retinol palmitate
retinyl (palmitate)
AMY13840
HY-B1384
CS-0013116
retinyl palmitate (vitamin a palmitate; retinol palmitate)
retinyl-palmitate
C76552
MS-29721
all-trans-retinylpalmitate-d5(major)
retinylpalmitate
vae 16:0
retinyl-10,11-14c2
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenyl hexadecanoate
retinol-15-3h
vitamin a (as palmitate & beta carotene)
o(15)-hexadecanoylretinol
chebi:15040
palmitate-1-14c
retinol hexadecanoate
retinyl palmitate (usp-rs)

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Retinol palmitate could be a treatment option for human brain infarction."( Retinol palmitate prevents ischemia-induced cell changes in hippocampal neurons through the Notch1 signaling pathway in mice.
Ito, H; Kuwabara, S; Mori, M; Sato, Y; Shimada, J; Takuwa, H; Taniguchi, J, 2013
)
2.55

Toxicity

ExcerptReferenceRelevance
" 13-cis-retinoic acid (CRA) was less toxic at 700 IU/g diet than was RP at that dose, as evidenced by the death of 12 of 70 mice by the 6th week of dietary RP and no deaths in the 35 mice fed 700 IU CRA/g diet for 23 weeks."( Osteotoxicity after chronic dietary administration of 13-cis-retinoic acid, retinyl palmitate or selenium in mice exposed to tumor initiation and promotion.
Forsyth, KS; Gensler, HL; Watson, RR, 1989
)
0.28
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" In conclusion, the nanoparticles containing antioxidant actives were safe for topical use and presented anti-aging activity in vivo and are suitable to be used as cosmetic ingredient."( Safety and efficacy of antioxidants-loaded nanoparticles for an anti-aging application.
Bruschi, M; Carvalho, AR; Felippi, CC; Oliveira, D; Raffin, RP; Ströher, A; Van Etten, EA, 2012
)
0.38
" Safety measures included clinical blood and urine analyses and adverse event recordings."( Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial.
Ebihara, N; Funaki, T; Kato, T; Murakami, A; Ono, K; Otake, H; Seki, T; Tabuchi, N; Toshida, H; Watanabe, S, 2017
)
0.77
"VApal ophthalmic solution (500 IU/mL) is safe and effective for the treatment of patients with dry eye."( Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial.
Ebihara, N; Funaki, T; Kato, T; Murakami, A; Ono, K; Otake, H; Seki, T; Tabuchi, N; Toshida, H; Watanabe, S, 2017
)
0.77

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic model fits showed that about half of the oral talinolol dose given with and without meal is drained from the intestine via a presystemic storage compartment."( The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Bernsdorf, A; Giessmann, T; Hartmann, V; Modess, C; Mrazek, C; Nagel, S; Siegmund, W; Wegner, D; Weitschies, W; Zschiesche, M, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"A challenge for cosmetic and dermatologic products is to develop new high-performance and safer anti-aging products based on new compounds to enhance the stability of retinyl palmitate combined with broad-spectrum UV-filters."( Effects of UV-filter Photostabilizers in the Photostability and Phototoxicity of Vitamin A Palmitate Combined with Avobenzone and Octyl Methoxycinnamate.
Benevenuto, CG; Gaspar, LR; Kawakami, CM; Pereira, KC; Rangel, KC; Scarpin, MS, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" The retinyl palmitate absorption rate constants were similar in control and pancreatitis patients."( Catabolism of chylomicron remnants in patients with previous acute pancreatitis.
Guzmán, S; Nervi, F; Pimentel, F; Rollán, A, 1990
)
0.28
"2 or 57 IU/kg) to examine the influence of vitamin concentrations on vitamin bioavailability and leukocyte functions."( Leukocyte functions of young dairy calves fed milk replacers supplemented with vitamins A and E.
Anderson, NV; Blecha, F; Chitko-McKown, CG; Eicher, SD; Higgins, JJ; Morrill, JL, 1994
)
0.29
"The effect of the ingestion of beta-carotene with medium-chain triglycerides (MCT) or long-chain triglycerides (LCT) on the bioavailability and the provitamin A activity of beta-carotene was investigated in humans."( Chylomicron beta-carotene and retinyl palmitate responses are dramatically diminished when men ingest beta-carotene with medium-chain rather than long-chain triglycerides.
Alexandre-Gouabau, MC; Azaïs-Braesco, V; Borel, P; Grolier, P; Lairon, D; Mekki, N; Rochette, Y; Tyssandier, V, 1998
)
0.3
"To assess the bioavailability of vitamins A and E administered parenterally with either water-soluble or lipid-soluble preparations."( Losses of vitamin A and E in parenteral nutrition suitable for premature infants.
Genzel-Boroviczény, O; Haas, C; Koletzko, B, 2002
)
0.31
"The effect of citric pectin on the bioavailability of synthetic beta-carotene was studied."( Effect of citric pectin on beta-carotene bioavailability in rats.
Fávaro, RM; Jordão Júnior, AA; Meirelles, MS; Vannucchi, H; Zanutto, ME, 2002
)
0.31
"The aims of this clinical study were to determine whether plant sterols affect the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic men and to compare the effects of plant sterol esters and plant free sterols on cholesterol absorption."( Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic humans.
Berger, A; Enslen, M; Fay, LB; Godin, JP; Green, H; Groux, M; Hager, C; Métairon, S; Piguet-Welsch, C; Quaile, S; Richelle, M; Sagalowicz, L; Tavazzi, I, 2004
)
0.32
" Plant free sterols and plant sterol esters reduced the bioavailability of beta-carotene by approximately 50% and that of alpha-tocopherol by approximately 20%."( Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic humans.
Berger, A; Enslen, M; Fay, LB; Godin, JP; Green, H; Groux, M; Hager, C; Métairon, S; Piguet-Welsch, C; Quaile, S; Richelle, M; Sagalowicz, L; Tavazzi, I, 2004
)
0.32
"Both plant sterols reduced beta-carotene and alpha-tocopherol bioavailability and cholesterol absorption in normocholesterolemic men."( Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic humans.
Berger, A; Enslen, M; Fay, LB; Godin, JP; Green, H; Groux, M; Hager, C; Métairon, S; Piguet-Welsch, C; Quaile, S; Richelle, M; Sagalowicz, L; Tavazzi, I, 2004
)
0.32
"Evaluation of the double-peak phenomenon during absorption of the beta(1)-selective blocker talinolol relative to paracetamol, which is well absorbed from all parts of the gut, and relative to vitamin A, which is absorbed via the lymphatic pathway."( The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Bernsdorf, A; Giessmann, T; Hartmann, V; Modess, C; Mrazek, C; Nagel, S; Siegmund, W; Wegner, D; Weitschies, W; Zschiesche, M, 2005
)
0.33
"Bioavailability of talinolol in enteric-coated and rectal capsules was significantly reduced by about 50% and 80%, respectively, despite unchanged bioavailability of paracetamol."( The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Bernsdorf, A; Giessmann, T; Hartmann, V; Modess, C; Mrazek, C; Nagel, S; Siegmund, W; Wegner, D; Weitschies, W; Zschiesche, M, 2005
)
0.33
"Improving the bioavailability of beta-carotene is vital to manage vitamin A deficiency."( Micellar oleic and eicosapentaenoic acid but not linoleic acid influences the beta-carotene uptake and its cleavage into retinol in rats.
Baskaran, V; Krishnakantha, TP; Lakshminarayana, R; Raju, M, 2006
)
0.33
"To assess the predictive value of a 3-point versus 7-point post-prandial response (area under the curve) in nutrient bioavailability studies in humans."( Suitability of 3-point versus 7-point postprandial retinyl palmitate AUC in human bioavailability studies.
Granado-Lorencio, F; Herrero-Barbudo, C; Olmedilla-Alonso, B, 2008
)
0.35
"We used results from a human bioavailability study (n = 19) that consisted of a single-dose pharmacokinetic assay involving three types of commercially available vitamin A and E fortified milk."( Suitability of 3-point versus 7-point postprandial retinyl palmitate AUC in human bioavailability studies.
Granado-Lorencio, F; Herrero-Barbudo, C; Olmedilla-Alonso, B, 2008
)
0.35
"The use of the 3-point approach may be a reliable alternative to assess the relative postprandial lipid response in human bioavailability studies."( Suitability of 3-point versus 7-point postprandial retinyl palmitate AUC in human bioavailability studies.
Granado-Lorencio, F; Herrero-Barbudo, C; Olmedilla-Alonso, B, 2008
)
0.35
"beta-Carotene (BC) is a potent dietary source of vitamin A for populations at risk of vitamin A deficiency, yet its bioavailability is influenced by several factors such as dietary fat, carotenoids type, and other components."( Bioefficacy of beta-carotene is improved in rats after solubilized as equimolar dose of beta-carotene and lutein in phospholipid-mixed micelles.
Baskaran, V; Marisiddaiah, R, 2009
)
0.35
"Iron bioavailability seems to be regulated by vitamin A (VA) but the molecular events involved in this mechanism are not well understood."( Vitamin A modulates the expression of genes involved in iron bioavailability.
Bittencourt, LL; Citelli, M; da Silva, SV; Pedrosa, C; Pierucci, AP, 2012
)
0.38
" Cassava is a staple food in the African diet, but data regarding the human bioavailability of β-carotene from this food are scarce."( Biofortified cassava increases β-carotene and vitamin A concentrations in the TAG-rich plasma layer of American women.
Burnett, DJ; Burri, BJ; La Frano, MR; Woodhouse, LR, 2013
)
0.39
"Maternal supplementation with high doses of vitamin A increased the colostrum level of this nutrient but reduced the bioavailability of α-tocopherol, which may harm the newborn's health because newborns have limited vitamin E reserves."( Maternal supplementation with a megadose of vitamin A reduces colostrum level of α-tocopherol: a randomised controlled trial.
Dimenstein, R; Grilo, EC; Gurgel, CS; Medeiros, WF; Ramalho, HM; Silva, AG, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The more retinol palmitate was injected, the more CL was observed. A dose-response relationship between the dose and the degree of duplication was not found.

ExcerptRelevanceReference
" A direct dose-response effect was observed, in that the more retinol palmitate was injected, the more CL was observed."( In vivo and in vitro studies on the effects of vitamin A on the chemiluminescent response of murine peritoneal exudate cells.
Caren, LD; Guzman, JJ; Marks, JF, 1991
)
0.52
" Controls (vitamin A adequate) were orally dosed weekly with 2 mg of retinyl palmitate."( Reduced survival of neonates due to vitamin A deficiency during pregnancy in the guinea pig.
Apgar, J; Dulin, A; Kramer, T; Smith, JC, 1991
)
0.28
" An oral dosing study of four normal individuals showed a wide variation of beta-carotene uptake."( Endogenous levels of beta-carotene in human buccal mucosa cells by reversed-phase high-performance liquid chromatography.
Culling-Berglund, AJ; Davis, TP; Newcomb, SA, 1990
)
0.28
" In rats dosed with 40 mg/kg, food consumption and growth as well as liver retinol and retinyl palmitate concentrations decreased, while serum retinol and liver weight increased within 28 days following the injection."( Increased retinoic acid metabolism following 3,3',4,4',5,5'-hexabromobiphenyl injection.
Garcin, H; Narbonne, JF; Spear, PA, 1988
)
0.27
" A dose-response relationship between the dose of retinol palmitate and either the percentage of limbs duplicated or the degree of duplication was not found."( The effects of two retinoids on limb regeneration in Pleurodeles waltl and Triturus vulgaris.
Carey, F; Lheureux, E; Thoms, SD, 1986
)
0.52
"Systemic vitamin A palmitate at three dosage levels was evaluated for its effect on experimental herpes simplex virus (HSV) keratitis in corticosteroid-treated rabbits."( Vitamin A in experimental herpetic keratitis.
Briones, O; Dawson, CR; Oh, J; Starr, MB, 1981
)
0.26
" Lysis of erythrocytes from -E rats was further increased by dosing with both the vitamins "A" and "C", the latter being more effective."( Effect of dietary protein and hypervitaminosis A or C on tissue peroxidation and erythrocyte lysis of vitamin E deficiency.
George, T; Jayanthi Bai, N; Krishnamurthy, S; Sanjeev Kumar, P, 1982
)
0.26
" This dosage level was embryolethal and teratogenic in the Fischer 344 rat."( Teratogenic effects of vitamin A palmitate in Fischer 344 rats.
Cobel-Geard, SR; Freshour, NL; Hanley, TR; Hayes, WC; John, JA; Murray, JS; Rao, KS, 1981
)
0.26
" Rats were divided into low (7500 IU) and high (50000 IU) dosage groups based on the dosage of vitamin A administered."( [Morphological changes in the knee joint of rat by intra-articular injection of vitamin A].
Kimura, Y, 1994
)
0.29
" In the initial 3-week dose-response study, as the daily dose of VA increased so did the degree of potentiation of CCl4 hepatotoxicity."( Characterization of vitamin A potentiation of carbon tetrachloride-induced liver injury.
Earnest, DL; elSisi, AE; Hall, P; Sim, WL; Sipes, IG, 1993
)
0.29
" Therefore, prepubertal retinyl palmitate treatment at the dosage administered had no effect on uterine capacity."( Effect of prepubertal retinyl palmitate treatment on uterine development and subsequent uterine capacity in swine.
Christenson, RK; Vallet, JL, 1996
)
0.29
"Retinoid pharmacokinetics were examined in plasma, placenta and embryos of gestational d 12 rabbits following application of an embryotoxic dosing regimen (10 mg retinyl palmitate/kg body wt per day from gestational d 7 to 12)."( Embryotoxic doses of vitamin A to rabbits result in low plasma but high embryonic concentrations of all-trans-retinoic acid: risk of vitamin A exposure in humans.
Bürgin, H; Collins, MD; Hummler, H; Nau, H; Tzimas, G, 1996
)
0.29
"05% under occlusion produced a linear dose-response induction of 4-hydroxylase activity."( Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid.
Duell, EA; Kang, S; Voorhees, JJ, 1997
)
0.3
" These dosed sera were also used to culture rat embryos."( Model predicting the teratogenic potential of retinyl palmitate, using a combined in vivo/in vitro approach.
Eckhoff, C; Oakes, DJ; Ritchie, HE; Webster, WS,
)
0.13
" In contrast to membranous vesicles, SLN can also be stably incorporated in convenient topical dosage forms like hydrogels or creams."( Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties.
Gohla, S; Jenning, V; Schäfer-Korting, M, 2000
)
0.31
" Results show that red palm oil groups recorded more gain in retinol and beta-carotene levels compared to other dosage groups, and that administration of 10 ml did not offer any substantial improvement over the 5-ml daily dose."( Impact of vitamin A supplementation through different dosages of red palm oil and retinol palmitate on preschool children.
Alwin Jayakumar, Y; Arumughan, C; Damodaran, M; Deepa, SS; Jayalekshmy, A; Raman Kutty, V; Sankara Sarma, P; Sivan, YS; Soban Kumar, DR; Soman, CR; Suja, KP; Sundaresan, A, 2002
)
0.54
"Male Wistar rats that underwent biliary obstruction were treated 2 weeks before the surgery with a dose of 50 x 10(3) IU retinyl-palmitate, twice a week, and then given the dosage for 5 weeks following surgery."( Retinyl-palmitate reduces liver fibrosis induced by biliary obstruction in rats.
Bustorff-Silva, JM; Castro e Silva Junior, O; de Freitas Junior, S; Jorge, Gde L; Leonardi, LS,
)
0.13
" Vitamin A status was evaluated by the modified relative dose-response (MRDR) technique."( The effect of retinyl palmitate added to iron-fortified maize porridge on erythrocyte incorporation of iron in African children with vitamin A deficiency.
Adou, P; Davidsson, L; Hurrell, R; Walczyk, T; Zeder, C, 2003
)
0.32
" On the other hand, co-administration of 10mg/kg pyridoxine, at ED 9 and 10, significantly increased the frequencies of anomalies, even in the moderate dosage (500 mg/kg) group."( Pyridoxine might not have a preventive effect on the retinyl palmitate-induced viscerocranial anomalies.
Ay, H; Ulupinar, E; Unal, N, 2010
)
0.36
" The RP dosage was 7,000 IU/kg of BW, and dosage of the KLH was 1 mg/kg of BW."( Retinyl palmitate does not have an adjuvant effect on the antibody response of chicks to keyhole limpet hemocyanin regardless of vitamin A status.
Klasing, KC; Livingston, KA, 2011
)
0.37
" Infants' VA liver stores were assessed by the modified relative dose-response (MRDR) test."( High prevalence of vitamin A deficiency is detected by the modified relative dose-response test in six-month-old Senegalese breast-fed infants.
Agne-Djigo, A; Idohou-Dossou, N; Kwadjode, KM; Tanumihardjo, SA; Wade, S, 2012
)
0.38
" Antioxidant and antitumor effects, with controversies over dosage and route of administration, were observed for the test compounds in their isolated form or associated in clinical studies."( Retinol palmitate and ascorbic acid: Role in oncological prevention and therapy.
Alencar, MVOB; da Mata, AMO; da Rocha Sousa, L; da Silva, FCC; de Carvalho Melo-Cavalcante, AA; de Carvalho, RM; de Castro E Sousaa, JM; de Oliveira Santos, JV; Ferreira, PMP; Gonçalves, JCR; Islam, MT; Mendes, AN; Nunes, NMF; Paz, MFCJ, 2019
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (7 Items)

ItemProcessFrequency
Yogurtscore-ingredient1
Fermented dairy dessertscore-ingredient1
Dairy dessertscore-ingredient1
Fermented milk productscore-ingredient1
Dessertscore-ingredient1
Fermented foodscore-ingredient1
Dairiescore-ingredient1

Roles (3)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
retinyl palmitateA palmitate ester of retinol with undefined geometry about the C=C bonds.
all-trans-retinyl esterA retintinyl ester in which all double bonds of the retinyl side-chain have trans-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (16)

PathwayProteinsCompounds
Digestion and absorption1724
Digestion1223
Digestion of dietary lipid36
Metabolism14961108
Metabolism of lipids500463
Triglyceride metabolism1317
Triglyceride catabolism1013
Wax and plasmalogen biosynthesis715
Metabolism of vitamins and cofactors146155
Metabolism of fat-soluble vitamins2623
Retinoid metabolism and transport2217
Visual phototransduction6241
Retinol Metabolism3730
Vitamin A Deficiency3730
Wax biosynthesis410
Sensory Perception21568

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency21.85280.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency6.11310.000714.592883.7951AID1259369
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency24.33650.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.56780.000229.305416,493.5996AID743069
GVesicular stomatitis virusPotency13.45040.01238.964839.8107AID1645842
heat shock protein beta-1Homo sapiens (human)Potency54.94100.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.85580.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency6.30960.00798.23321,122.0200AID2546
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency39.81076.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency13.45040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (68)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID404776Induction of CRABP 2 mRNA expression in human normal fibroblast at 10 uM by Western blot relative to control2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID404775Induction of CRABP 2 mRNA expression in human normal fibroblast at 1 uM by Western blot relative to control2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (894)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990211 (23.60)18.7374
1990's306 (34.23)18.2507
2000's178 (19.91)29.6817
2010's174 (19.46)24.3611
2020's25 (2.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.57 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index128.35 (26.88)
Search Engine Supply Index3.96 (0.95)

This Compound (40.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials132 (13.88%)5.53%
Reviews32 (3.36%)6.00%
Case Studies22 (2.31%)4.05%
Observational0 (0.00%)0.25%
Other765 (80.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (52)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vitamin A Equivalence of Carotenoids From Cassava in Women [NCT01381276]Phase 210 participants (Actual)Interventional2011-06-30Completed
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid [NCT02339740]Phase 3158 participants (Actual)Interventional2015-07-21Active, not recruiting
[NCT03112382]Phase 480 participants (Anticipated)Interventional2015-11-30Completed
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO) [NCT01409161]Phase 2151 participants (Anticipated)Interventional2011-10-05Recruiting
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]Phase 12 participants (Actual)Interventional2020-04-01Active, not recruiting
Effect of Dietary DHA Supplementation on Cognitive Performance and Growth in Chinese School Children: A Randomized Controlled Study [NCT02308930]106 participants (Actual)Interventional2014-07-31Active, not recruiting
Vitamin A in Sickle Cell Disease: Improving Sub-optimal Status With Supplementation [NCT03632876]42 participants (Actual)Interventional2015-10-02Completed
Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial [NCT01152931]Phase 310 participants (Actual)Interventional2010-08-31Completed
Assessing the Cosmetic Changes in the Facial Skin Utilizing Non-Invasive In Vivo Skin Imaging Instrumentation After Use of a Topical Retinoid Product In Subjects With Moderate to Severe Photodamage [NCT03302559]29 participants (Actual)Interventional2017-09-18Completed
Vitamin A Supplementation of Breast Feeding Mothers and Their Neonates at Delivery: Impact on Mother to Child Transmission of HIV During Lactation, HIV Infection Among Women During the Postpartum Year, and Infant Mortality. [NCT00198718]Phase 228,220 participants (Actual)Interventional1997-11-30Completed
The Effect of Encapsulation Material and Encapsulated Micronutrients on Iron Absorption in Iron Depleted Women Consuming Iron Fortified Bread. [NCT03332602]24 participants (Actual)Interventional2018-04-04Completed
Single, High Dose Vitamin A Replacement in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT03719092]34 participants (Anticipated)Interventional2020-02-07Recruiting
A Randomized Controlled Trial of Antibody Responses by Vitamin Supplementation at the Time of Pneumococcus Vaccination in Children [NCT03859687]Phase 180 participants (Anticipated)Interventional2019-08-19Recruiting
LOAEL/NOAEL and UL Determination in Guatemala - Estimation of Vitamin A Stores in Children and Women and Correlation With Potential Toxicity Markers [NCT03345147]178 participants (Actual)Observational2017-01-13Completed
[NCT02077231]30 participants (Actual)Interventional2011-09-30Completed
Effect of Protein and Retinol on Alcohol-induced FGF21 [NCT06105476]30 participants (Anticipated)Interventional2023-11-20Recruiting
An Investigation of Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation [NCT03478878]Early Phase 120 participants (Anticipated)Interventional2018-05-14Recruiting
Pilot Feasibility of Rice Bran Supplementation for Diarrheal Disease Prevention in Malian Children [NCT02557373]48 participants (Actual)Interventional2015-08-31Completed
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation [NCT00866918]Phase 3106 participants (Actual)Interventional2009-03-09Completed
Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants [NCT00642863]1,614 participants (Actual)Interventional2008-04-30Completed
The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children [NCT02878265]Phase 3547 participants (Actual)Interventional2011-11-30Completed
A Double Blind, Placebo Controlled Randomized Trial of Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Children Aged 5-14 Years With Latent Tuberculosis. [NCT00558480]0 participants (Actual)Interventional2009-07-31Withdrawn
Vitamins, Breastmilk HIV Shedding, and Child Health [NCT00197756]771 participants (Actual)Observational2004-09-30Completed
[NCT00378456]0 participants InterventionalCompleted
Stopping Postpartum Vitamin A Supplementation: Are we Missing Concealed Benefit? [NCT02043223]Phase 2/Phase 3160 participants (Actual)Interventional2013-10-31Completed
An Investigation of Vitamin A Palmitate Supplementation in Patients With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation [NCT03478865]Early Phase 120 participants (Anticipated)Interventional2018-04-20Recruiting
A Pilot Study of Neoadjuvant High Dose Vitamin A for Resectable Non-Small Cell Lung Cancer [NCT03870529]Early Phase 120 participants (Actual)Interventional2019-08-19Terminated(stopped due to Slow accruals)
Effects of Intermittent Iron and Vitamin A Supplementation on Nutritional Status and Development of Schoolchildren in Arba Minch Zuria District, Ethiopia. [NCT04137354]504 participants (Actual)Interventional2020-11-02Completed
Timing, Duration and Severity of Infant Iron Deficiency: Developmental Impacts [NCT00613717]2,371 participants (Actual)Interventional2009-11-30Completed
The Role of Sub-clinical Inflammation on the Iron Status of Myanmar Anaemic Adolescent Schoolgirls During Iron and Vitamin A Supplementation [NCT01198574]Phase 3402 participants (Actual)Interventional2010-07-31Completed
Chengdu Women's and Children's Central Hospital [NCT02675140]Phase 4209 participants (Actual)Interventional2012-03-31Completed
A Randomized Controlled Trial in Human Neonates to Determine the Effect of Vitamin A Supplementation on Immune Responses [NCT01476358]Phase 2200 participants (Anticipated)Interventional2011-11-30Active, not recruiting
Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function [NCT01583972]300 participants (Actual)Interventional2012-01-31Completed
Effect of Daily Consumption of β-carotene Biofortified Maize on Milk Retinol Concentration in Lactating Zambian Women [NCT01922713]149 participants (Actual)Interventional2013-10-31Completed
Treatment of Acne for Cases Resistant to Currently Available Measures Via Vitamin A With or Without Azithromycin in Topical Formulations [NCT03090048]Early Phase 130 participants (Anticipated)Interventional2021-04-01Not yet recruiting
Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children [NCT00272116]2,482 participants (Actual)Interventional1998-02-28Completed
The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa [NCT00133419]Phase 2516 participants InterventionalCompleted
A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer [NCT04919369]Phase 118 participants (Anticipated)Interventional2021-10-18Recruiting
Efficacy of Daily Consumption of Sweet Potatoes for Increasing Total Body Vitamin A Pool Size, and the Effect of Consumption of Sweet Potatoes on Iron and Zinc Absorption in Bangladeshi Women of Reproductive Age [NCT00453648]130 participants (Actual)Interventional2006-03-31Completed
Vitamin A Supplementation in Newborns Study [NCT00114868]Phase 314,035 participants (Actual)Interventional1998-06-30Completed
Does Additional Vitamin A Supplementation Improve Retinal Function and Conjunctival Health in Very Low Birthweight Infants? [NCT00417404]Phase 494 participants (Actual)Interventional2007-01-31Completed
Responsiveness of RDR Test to Assess Hepatic Vitamin A Stores in Chronic Liver Disease [NCT01634698]178 participants (Actual)Interventional2007-10-31Completed
Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients [NCT01705457]Phase 420 participants (Anticipated)Interventional2010-02-28Enrolling by invitation
A Randomised Controlled Home-based Trial of the Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants. [NCT01751009]93 participants (Actual)Interventional2010-01-31Completed
Evaluation of the Impact of Vitamin A and Zinc Supplementation on Malarial Morbidity in Ghana [NCT01782001]Phase 3200 participants (Actual)Interventional2009-03-31Completed
Effect of Small Daily Doses of B-carotene or Vitamin A on Breast Milk Retinol Concentration in Lactating Filipino Women. [NCT01803659]85 participants (Actual)Interventional2013-01-31Completed
Comparison of the Cosmetic Effects of Bakuchiol and Retinol [NCT03112863]Early Phase 144 participants (Actual)Interventional2017-03-24Completed
Characterization of Night Vision Impairment in Choroideremia and Short-Term Vitamin A Supplementation: The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study [NCT05045703]0 participants (Actual)Interventional2023-05-31Withdrawn(stopped due to PI left the institution)
Formulation of Retinyl Palmitate-loaded Topical Ethosomes for Treatment of Acne Vulgaris: a Split-face Comparative Clinical Study [NCT04080869]Phase 220 participants (Actual)Interventional2020-01-06Completed
Norwegian Mother and Child Study - Causal Pathways for Asthma (CASPAR) [NCT03197233]61,676 participants (Actual)Observational1999-01-31Completed
The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis [NCT01225289]Phase 436 participants (Actual)Interventional2009-10-31Completed
Vitamin A Kinetics and Mathematical Modeling in American Women [NCT03248700]8 participants (Actual)Interventional2008-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00866918 (4) [back to overview]Event-free Survival (EFS)
NCT00866918 (4) [back to overview]Hematologic Remission Rate
NCT00866918 (4) [back to overview]Hematologic, Molecular, and Cytogenetic Remission Rate
NCT00866918 (4) [back to overview]Overall Survival (OS)
NCT01198574 (3) [back to overview]Haemoglobin Level
NCT01198574 (3) [back to overview]Status of Cellular Iron Deficiency
NCT01198574 (3) [back to overview]Status of Tissue Iron Store
NCT01225289 (4) [back to overview]Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation
NCT01225289 (4) [back to overview]Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation
NCT01225289 (4) [back to overview]Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation
NCT01225289 (4) [back to overview]Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)
NCT02339740 (2) [back to overview]EFS in High Risk APL Patients
NCT02339740 (2) [back to overview]Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients
NCT03112863 (4) [back to overview]Change in Wrinkle Appearance
NCT03112863 (4) [back to overview]Number of Reports of Facial Erythema Assessment
NCT03112863 (4) [back to overview]Number of Reports of Stinging, Burning, Itching
NCT03112863 (4) [back to overview]Percentage of Participants With Change in Appearance of Skin Pigmentation
NCT03302559 (11) [back to overview]Investigator's Global Improvement Assessment for Overall Photodamage
NCT03302559 (11) [back to overview]Investigator's Global Improvement Assessment for Tactile Roughness
NCT03302559 (11) [back to overview]Change From Baseline in Appearance of Coarse Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed)
NCT03302559 (11) [back to overview]Change From Baseline in Appearance of Fine Lines Score Using the Allergan Fine Lines Visual Scale
NCT03302559 (11) [back to overview]Change From Baseline in Appearance of Fine Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed)
NCT03302559 (11) [back to overview]Change From Baseline in Overall Photodamage Score
NCT03302559 (11) [back to overview]Change From Baseline in Skin Roughness Score Using the Allergan Skin Roughness Visual Scale
NCT03302559 (11) [back to overview]Change From Baseline in Spectrophotometer L* Value (a Measurement of Skin Brightness)
NCT03302559 (11) [back to overview]Change From Baseline in Tactile Roughness Score
NCT03302559 (11) [back to overview]Investigator's Global Improvement Assessment for the Appearance of Coarse Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed)
NCT03302559 (11) [back to overview]Investigator's Global Improvement Assessment for the Appearance of Fine Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed)

Event-free Survival (EFS)

EFS - time from study entry until failure to achieve complete remission during consolidation, relapse, or death. For further clarification see definitions provided in the protocol. (NCT00866918)
Timeframe: At 3 years from study entry

InterventionPercentage of participants (Number)
Standard Risk95.4
High Risk82.9

[back to top]

Hematologic Remission Rate

Proportion of patients in hematologic remission at end of consolidation, course 1 are reported. (NCT00866918)
Timeframe: End of consolidation, course 1: up to 5 months

InterventionProportion of participants (Number)
Standard Risk1.0000
High Risk0.8824

[back to top]

Hematologic, Molecular, and Cytogenetic Remission Rate

Proportion of patients in hematologic, molecular, and cytogenetic remission at end of consolidation, course 3 and 4 are reported. Patients were determined to be in remission by all three criteria. (NCT00866918)
Timeframe: End of consolidation, course 3; up to 7 months (for Standard Risk) or end of consolidation, course 4; up to 9 months (for High Risk)

InterventionProportion of participants (Number)
Standard Risk0.8095
High Risk0.5882

[back to top]

Overall Survival (OS)

OS - time from study entry to death. (NCT00866918)
Timeframe: At 3 years from study entry

InterventionPercentage of participants (Number)
Standard Risk98.4
High Risk85.7

[back to top]

Haemoglobin Level

Haemoglobin level (g/L) measured by cyanmethaemoglobin method (NCT01198574)
Timeframe: at week 0, week 6 and week12

,,,
Interventiong/L (Mean)
Hb week 0 (Baseline)Hb week 6 (Midline)Hb week 12 (Endline)
Iron and Vitamin A Group88.499.2111.4
Iron Group88.398.1110.8
Placebo Group89.698.3109.7
Vitamin A Group89.298.7109.0

[back to top]

Status of Cellular Iron Deficiency

Cellular Iron deficiency status is also measured by serum transferrin receptor (NCT01198574)
Timeframe: at week 0, week 6 and week12

,,,
Interventionmg/L (Geometric Mean)
serum transferrin receptor (Baseline)serum transferrin receptor (Midline)serum transferrin receptor (Endline)
Iron and Vitamin A Group7.166.736.24
Iron Group7.096.696.44
Placebo Group6.746.596.61
Vitamin A Group6.566.396.27

[back to top]

Status of Tissue Iron Store

Tissue iron store was measured by serum ferritin (NCT01198574)
Timeframe: at week 0, week 6 and week12

,,,
Interventionµg/L (Geometric Mean)
serum ferritin (Baseline)serum ferritin (Midline)serum ferritin (Endline)
Iron and Vitamin A Group25.932.335.4
Iron Group32.134.539.6
Placebo Group31.126.528.2
Vitamin A Group34.432.135.0

[back to top]

Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation

(NCT01225289)
Timeframe: first day and after 6 month

Interventionpg/ml (Mean)
With Multiple Sclerosis/ Vitamin A2.5
With Multiple Sclerosis/ Placebo1.5

[back to top]

Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation

(NCT01225289)
Timeframe: first day and after 6 month

Interventionratio (Mean)
With Multiple Sclerosis/ Vitamin A0.2
With Multiple Sclerosis/ Placebo-0.4

[back to top]

Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation

(NCT01225289)
Timeframe: first day and after 6 month

Interventionmg/L (Mean)
With Multiple Sclerosis/ Vitamin A1.2
With Multiple Sclerosis/ Placebo-0.6

[back to top]

Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)

difference of PBMCs proliferation stimulated with myelin oligodendrocyte glycoprotein (MOG), before and after of supplementation (NCT01225289)
Timeframe: first day and after 6 month

Interventionabsorbance units (Mean)
With Multiple Sclerosis/ Vitamin A-0.06
With Multiple Sclerosis/ Placebo-0.13

[back to top]

EFS in High Risk APL Patients

EFS is defined as the time from on study to failure to achieve hematological CR prior to start of consolidation, persistence of molecular positive disease after MRD positive consolidation course, relapse (molecular, morphologic or extramedullary), or death. The Kaplan-Meier method will be used to estimate 2-year EFS along with 90% log-minus-log transformed confidence limits. (NCT02339740)
Timeframe: Up to 24 months

Interventionpercentage of participants (Number)
High Risk96.1

[back to top]

Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients

EFS is defined as the time from on study to failure to achieve hematological complete response (CR) prior to start of consolidation, persistence of molecular positive disease after minimal residual disease (MRD) positive consolidation course, relapse (molecular, morphologic or extramedullary), or death. The Kaplan-Meier method will be used to estimate 2-year EFS along with 90% log-minus-log transformed confidence limits. (NCT02339740)
Timeframe: Up to 24 months

Interventionpercentage of participants (Number)
Standard Risk97.9

[back to top]

Change in Wrinkle Appearance

"Assessed using image analysis based assessment of wrinkle severity (depth and length).~The primary outcome measure was image-analysis-based assessment of wrinkle severity and pigmentation at 12 weeks." (NCT03112863)
Timeframe: 12 week

Interventionpercentage of reduced fine wrinkles (Number)
Bakuchiol19.0
Retinol23.2

[back to top]

Number of Reports of Facial Erythema Assessment

Image analysis based assessment of facial erythema (NCT03112863)
Timeframe: week 4, week 8 and week 12

Interventionreports (Number)
Bakuchiol0
Retinol0

[back to top]

Number of Reports of Stinging, Burning, Itching

Subjective tolerability assessment of stinging, burning, itching. Secondary outcome measures included redness, participant-reported tolerability (itching, burning and stinging) and in-person clinical assessments (pigmentation, scaling and erythema) throughout the study. (NCT03112863)
Timeframe: Assessed at Week 4, 8, and 12.

Interventionreports (Number)
Bakuchiol0
Retinol0

[back to top]

Percentage of Participants With Change in Appearance of Skin Pigmentation

Assessed using image analysis based assessment of facial pigment (NCT03112863)
Timeframe: 12 week

Interventionpercentage of participants (Number)
Bakuchiol59
Retinol44

[back to top]

Investigator's Global Improvement Assessment for Overall Photodamage

The investigator assessed the global improvement in the participant's overall photodamage compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Almost complete improvement of the condition with a trace of signs/symptoms remaining (approximately 95% or better overall improvement). (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Retinol Complex 0.51.5

[back to top]

Investigator's Global Improvement Assessment for Tactile Roughness

The investigator assessed the global improvement in the participant's overall tactile roughness compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Complete clearing in the appearance of tactile roughness (approximately 95% or better overall improvement). (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Retinol Complex 0.51.3

[back to top]

Change From Baseline in Appearance of Coarse Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed)

The investigator assessed the participant's appearance of coarse lines/wrinkles using a 10-point scale where None (0)= No coarse lines/wrinkles present; skin looks completely smooth and wrinkle-free to Severe (7 to 9)= Many coarse lines/wrinkles densely packed together in the treatment area (forehead, periocular, cheeks and perioral areas) at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Baseline (Forehead)Change from BL at Week 12 (Forehead)Baseline (Periocular)Change from Baseline at Week 12 (Periocular)Baseline (Cheeks)Change from Baseline at Week 12 (Cheeks)Baseline (Perioral)Change from BL at Week 12 (Perioral)
Retinol Complex 0.54.9-0.66.0-0.73.5-1.14.4-0.2

[back to top]

Change From Baseline in Appearance of Fine Lines Score Using the Allergan Fine Lines Visual Scale

The investigator assessed the participant's fine lines using the Allergan Fine Lines Visual 5-Point Scale where None (0)= No fine lines to Diffuse (4)= Diffuse superficial lines; crosshatching at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
BaselineChange from BL at Week 12
Retinol Complex 0.54.0-0.3

[back to top]

Change From Baseline in Appearance of Fine Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed)

The investigator assessed the participant's appearance of fine lines/wrinkles using a 10-point scale where None (0)= No fine lines/wrinkles present; skin looks completely smooth and wrinkle-free to Severe (7 to 9)= Many coarse lines/wrinkles densely packed together in the treatment area (forehead, periocular, cheeks and perioral areas) at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Baseline (Forehead)Change from BL at Week 12 (Forehead)Baseline (Periocular)Change from BL at Week 12 (Periocular)Baseline (Cheeks)Change from BL at Week 12 (Cheeks)Baseline (Perioral)Change from BL at Week 12 (Perioral)
Retinol Complex 0.53.4-0.84.7-1.03.6-1.14.0-0.9

[back to top]

Change From Baseline in Overall Photodamage Score

The investigator assessed the participant's overall photodamage using a 10-point scale where None (0)= Facial skin is smooth to the touch, without significant fine/coarse line or skin tone unevenness in any areas (periocular, cheeks, forehead and perioral areas) to Severe (7 to 9)= Facial skin shows 3 or more areas (periocular, cheeks, forehead and perioral areas) of significant roughness, skin tone unevenness (red/brown), or fine/coarse lines at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Baseline (BL)Change from BL at Week 12
Retinol Complex 0.55.6-0.8

[back to top]

Change From Baseline in Skin Roughness Score Using the Allergan Skin Roughness Visual Scale

The investigator assessed the participant's skin roughness using the Allergan Skin Roughness Visual 5-Point Scale where None (0)= Smooth visual skin texture to Extreme (4)= Extremely coarse visual skin texture, crosshatched deep creases; extreme elastosis at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
BaselineChange from BL at Week 12
Retinol Complex 0.51.8-0.5

[back to top]

Change From Baseline in Spectrophotometer L* Value (a Measurement of Skin Brightness)

Triplicate spectrophotometer readings were taken of the participant's face (Normal Skin and Target Lesions) at Baseline and Week 12. L* value scores range from 0=black to 100=white. An increase in the spectrophotometer L* values indicates improvement. A positive change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Baseline (Normal Skin)Change from BL at Week 12 (Normal Skin)Baseline (Target Lesion)Change from BL at Week 12 (Target Lesion)
Retinol Complex 0.562.00.357.80.3

[back to top]

Change From Baseline in Tactile Roughness Score

The investigator assessed the participant's tactile roughness in the entire face using a 10-point scale where None (0)= No roughness of the treatment area; skin is completely smooth and pliable to Severe (7 to 9)= Marked roughness of the treatment area associated with stiff feeling at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement. (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
BaselineChange from BL at Week 12
Retinol Complex 0.54.0-1.1

[back to top]

Investigator's Global Improvement Assessment for the Appearance of Coarse Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed)

The investigator assessed the global improvement in the participant's overall appearance of coarse lines/wrinkles compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Complete clearing in the appearance of coarse lines/wrinkles (approximately 95% or better overall improvement). (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Week 12 (Forehead)Week 12 (Periocular)Week 12 (Cheeks)Week 12 (Perioral)
Retinol Complex 0.50.81.60.90.8

[back to top]

Investigator's Global Improvement Assessment for the Appearance of Fine Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed)

The investigator assessed the global improvement in the participant's overall appearance of fine lines/wrinkles compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Complete clearing in the appearance of fine lines/wrinkles (approximately 95% or better overall improvement). (NCT03302559)
Timeframe: Baseline (Day 1) to Week 12

Interventionscore on a scale (Mean)
Week 12 (Forehead)Week 12 (Periocular)Week 12 (Cheeks)Week 12 (Perioral)
Retinol Complex 0.51.11.61.31.2

[back to top]